# California Life Sciences: California Life Sciences > California Life Sciences \(CLS\) is the statewide trade association representing California's biotech, pharmaceutical, and medtech sector — a sector supporting over one million jobs and leading the nation in NIH funding and venture investment\. Generated by Yoast SEO v28.7, this is an llms.txt file, meant for consumption by LLMs. ## Pages - [About Us](https://www.califesciences.org/about-us/) - [Contact Us](https://www.califesciences.org/contact/) - [Privacy Policy](https://www.califesciences.org/privacy-policy/) - [Insights Blog](https://www.califesciences.org/insights/) - [News \& Updates](https://www.califesciences.org/news-updates/) - [Sector Report](https://www.califesciences.org/publications/sector-report/) ## News - [California Life Sciences Announces Winners of 22nd Annual Pantheon Awards](https://www.califesciences.org/news/california-life-sciences-announces-winners-of-22nd-annual-pantheon-awards/) - [California Life Sciences \(CLS\) Announces Winners of 23rd Annual Pantheon Awards](https://www.califesciences.org/news/cls-announces-2026-pantheon-winners/) - [A treatment in search of a disease – Legislation unnecessarily threatens California’s leadership in life sciences](https://www.califesciences.org/news/a-treatment-in-search-of-a-disease-legislation-unnecessarily-threatens-californias-leadership-in-life-sciences/): The success and productivity of California’s life sciences ecosystem rely on its unique, interconnected structure\. - [AB 1887 Signed Into Law](https://www.califesciences.org/news/ab-1887-signed-into-law/): Governor Gavin Newsom has signed AB 1887 into law — a critical step forward for California's rare disease community\. This legislation eliminates prior authorization and step therapy delays for FDA\-approved rare disease treatments, ensuring patients can access the care their doctors prescribe without unnecessary insurance red tape\. - [California Life Sciences Statement on AB 1776, the California COMPETE Act](https://www.califesciences.org/news/cls-statement-compete-act/): California's antitrust laws must take into account the impact the life sciences sector has had in our state and around the world – improving health outcomes and bringing lifesaving treatments to patients\. ## Our Members - [Stirbar Lab](https://www.califesciences.org/our_members/stirbar-lab/) - [Simisco Bio](https://www.califesciences.org/our_members/simisco-bio/) - [Cenos](https://www.califesciences.org/our_members/cenos/) - [Wilmerhale](https://www.califesciences.org/our_members/wilmerhale/) - [Voro](https://www.califesciences.org/our_members/voro/) ## Insights - [Meet the Winners and Finalists of the 23rd Annual Pantheon Awards](https://www.califesciences.org/insights/cls-announces-2026-pantheon-winners/): 2026 Pantheon Awards winners and finalists: meet the seven honorees and five Emerging Innovator finalists CLS will celebrate on November 12 in San Francisco\. - [From Lab to Patient: Key Takeaways from the 2026 Cell and Gene Therapy Symposium](https://www.califesciences.org/insights/cgt-symposium-2026-recap/) - [Beyond Expectations: Transforming Life Sciences With AI\-Powered Multi\-Omics Integration](https://www.califesciences.org/insights/ai-multi-omics-precision-medicine/): AI multi\-omics integration turns genomics, proteomics, and metabolomics data into predictive tools that are reshaping precision medicine and clinical care\. - [Maximizing Clinical Trial Access With AI](https://www.califesciences.org/insights/ai-clinical-trial-matching/): AI clinical trial matching uses large language models to pair patients with studies in minutes, easing the bottleneck that stalls nine in ten trial timelines\. - [FAIR Data Principles, Explained for Life Sciences Startups](https://www.califesciences.org/insights/fair-data-principles-life-sciences/): FAIR data principles, explained for life sciences startups: what the four mean in practice, why FAIR is not public, and where 96% of the cost lands\. ## Member Insights - [Accelerating the Path to IND: Integrated ADC and Bispecific Workflows](https://www.califesciences.org/member-insights/accelerating-the-path-to-ind-integrated-adc-and-bispecific-workflows/): The transition from lead candidate to Investigational New Drug \(IND\) filing is often delayed by the logistical complexity of managing multiple contract service providers\. Fragmented workflows, where cell line development, drug substance manufacturing, and fill\-finish occur at different sites, introduce analytical issues\. - [Five Key Areas of a Buyer’s Decision Qualification](https://www.califesciences.org/member-insights/five-key-areas-of-a-buyers-decision-qualification/): There are five key areas that sellers must understand from prospective customers that will be used to make a purchasing decision\. And we instruct our customers’ sellers to identify this information before they submit a proposal or quote\. - [Enhance Your Recruitment \& Retention Strategy For Rare Kidney Disease Trials](https://www.califesciences.org/member-insights/enhance-your-recruitment-retention-strategy-for-rare-kidney-disease-trials/): Breakthroughs in genetic understanding alongside the growing shift toward accommodating orphan drugs have led to an upswing in clinical trials for rare kidney diseases, of which there are 150\+ affecting patients worldwide\. - [September Update: Antibody Industry Trends \(Q3 2026 Insights, Trends \& Analysis\)](https://www.califesciences.org/member-insights/september-update-antibody-industry-trends-q3-2026-insights-trends-analysis/): Biointron’s Q3 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in July, August, and September\. This quarter, ten novel antibody\-based drugs have received first global approval\. - [How Australia’s Leading CRO Is Driving Biotech’s Acceleration From First\-In\-Human To Global Markets](https://www.califesciences.org/member-insights/how-australias-leading-cro-is-driving-biotechs-acceleration-from-first-in-human-to-global-markets/): CEO of Avance Clinical, Mark Harvill found his way into the clinical research space by chance, or perhaps more accurately, kismet\. ## Member News - [Dr\. Nimisha Srivastava Appointed Chief Executive Officer to Lead Slingshot Bio into Its Next Chapter](https://www.califesciences.org/member-news/nimisha-srivastava-appointed-chief-executive-officer-slingshot-bio/): Slingshot Biosciences, a leader in precision\-engineered cell mimics for flow cytometry, announced that Dr\. Nimisha Srivastava has been appointed Chief Executive Officer, effective September 23, 2026\. - [iNFixion seeks NF1 treatment by enhancing what the body is doing right](https://www.califesciences.org/member-news/infixion-seeks-nf1-treatment-by-enhancing-what-the-body-is-doing-right/): Since discovering his daughter’sNF1, a rare disease impacting 1 in 3000 people, nearly 25 years ago, Sarnoff has slowly transformed himself from a tech entrepreneur with limited knowledge of biology to leading iNFixion Bioscience, a biotech developing treatments for NF1\. - [BrainStorm Therapeutics combines brain organoids and AI for CNS drug discovery](https://www.califesciences.org/member-news/brainstorm-therapeutics-combines-brain-organoids-and-ai-for-cns-drug-discovery/): Artificial intelligence is opening new possibilities for drug discovery\. But in neuroscience, AI is only as powerful as the biological data behind it, and BrainStorm Therapeutics believes AI combined with human brain biology can be better\. - [Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS\-ALS Community Closer to a Potential Targeted Treatment](https://www.califesciences.org/member-news/otsuka-announces-transformative-phase-3-fusion-results-for-ulefnersen-bringing-the-fus-als-community-closer-to-a-potential-targeted-treatment/): Otsuka Pharmaceutical Development \& Commercialization, Inc\. and Ionis Pharmaceuticals, Inc\. today announced positive topline results from the Phase 3 FUSION trial evaluating ulefnersen, an investigational RNA\-targeted medicine, in people living with a genetic subtype of amyotrophic lateral sclerosis \(ALS\) known as FUS\-ALS, caused by mutations in the fused in sarcoma \(FUS\) gene\. - [Next\-Level Clinical Practice, Real\-World Impact: Evolving Patient Simulation with the Clinical Readiness Studio](https://www.califesciences.org/member-news/evolving-patient-simulation-medscape-clinical-readiness-studio/): In celebration of Health Simulation Week \(September 14\-18\), we are excited to introduce the Clinical Readiness Studio \(CRS\), an AI\-augmented simulation environment built to scale across 30\+ medical specialties\. ## Board Members - [Curtis Tyree](https://www.califesciences.org/board-member/curtis-tyree/) - [Joy Russell](https://www.califesciences.org/board-member/joy-russell/) - [Caryn McDowell](https://www.califesciences.org/board-member/caryn-mcdowell/) - [Nadir Mahmood, PhD](https://www.califesciences.org/board-member/nadir-mahmood/) - [Melinda Richter](https://www.califesciences.org/board-member/melinda-richter/) ## Team Members - [Aracely Campa Ramirez](https://www.califesciences.org/team/aracely-campa-ramirez/) - [Sarah Christie](https://www.califesciences.org/team/sarah-christie/) - [Patricia Ruiz Flinn](https://www.califesciences.org/team/patricia-ruiz-flinn/) - [Gina Aguirre](https://www.califesciences.org/team/gina-aguirre/) - [Leena Sanchez](https://www.califesciences.org/team/leena-sanchez/) ## Providers - [Office Depot Business](https://www.califesciences.org/provider/office-depot/) - [Goodwin Procter](https://www.califesciences.org/provider/goodwin-procter/) - [Singular Genomics](https://www.califesciences.org/provider/singular-genomics/) - [SaphoBio](https://www.califesciences.org/provider/saphobio/) - [FirmaTRUST](https://www.califesciences.org/provider/firmatrust/) ## Venues - [Washington, DC](https://www.califesciences.org/venue/washington-dc-2/) - [The Women's Building](https://www.califesciences.org/venue/the-womens-building/) - [San Mateo](https://www.califesciences.org/venue/san-mateo/) - [Mission Valley Branch Library](https://www.califesciences.org/venue/mission-valley-branch-library/) - [111 Minna Street](https://www.califesciences.org/venue/111-minna-street/) ## Hosts - [Halloran Consulting Group, Inc\.](https://www.califesciences.org/host/halloran-consulting-group-inc-2/) - [BIO](https://www.califesciences.org/host/bio/) - [CLS Member](https://www.califesciences.org/host/cls-member-events/) - [National Institute of Health](https://www.califesciences.org/host/national-institute-of-health-2/) - [The Leadership Edge](https://www.califesciences.org/host/the-leadership-edge-2/) ## Events - [Beakers \& Brews](https://www.califesciences.org/event/beakers-brews-oct-27-sd/): Join CLS members, startup leaders, service providers, and industry partners for an evening of learning and connection in a relaxed setting\. Each gathering begins with a one\-hour, practical training session focused on timely topics for emerging and growing companies, followed by informal networking over drinks\. - [Beakers \& Brews](https://www.califesciences.org/event/beakers-brews-oct-27-ssf/): Join CLS members, startup leaders, service providers, and industry partners for an evening of learning and connection in a relaxed setting\. Each gathering begins with a one\-hour, practical training session focused on timely topics for emerging and growing companies, followed by informal networking over drinks\. - [California Leadership Forum](https://www.califesciences.org/event/california-leadership-forum-2027/) - [Life Sciences Academy](https://www.califesciences.org/event/life-sciences-academy-2027/): Since its inception over ten years ago, CLS’s Life Sciences Academy has become the premier life sciences event for state lawmakers and industry leaders to address the most pressing issues facing our sector\. From patient access to innovative treatments, California companies are advancing the most innovative solutions for human health across our state and the world\. - [Cell \& Gene Therapy Symposium](https://www.califesciences.org/event/cell-gene-therapy-symposium-2027/): CLS, CIRM, and the UC San Diego Gene Therapy Initiative are leveraging their distinct expertise to deliver a 2\-day experience accessible to the Southern\-California life sciences and biotech ecosystem\. ## Series - [Legal Series: Launch, Grow, Succeed](https://www.califesciences.org/series/legal-series-launch-grow-succeed/) - [From the Laboratory to Leadership](https://www.califesciences.org/series/from-the-laboratory-to-leadership/) ## Contributors - [Royale International](https://www.califesciences.org/contributor/royale-international/) - [CleanSpace](https://www.califesciences.org/contributor/cleanspace/) - [Mike Guerra](https://www.califesciences.org/contributor/mike-guerra/) - [Medscape](https://www.califesciences.org/contributor/medscape/) - [Flannery Sales Systems](https://www.califesciences.org/contributor/flannery-sales-systems/) ## Service Categories - [Growth \& Business Operations](https://www.califesciences.org/service-category/growth-operations/) - [Lab Operations](https://www.califesciences.org/service-category/lab-operations/) - [CDMO \- Contract Manufacturing](https://www.califesciences.org/service-category/cdmo/) - [Scientific Operations](https://www.califesciences.org/service-category/scientific-operations/) - [CRO \- Research \& Clinical Services](https://www.califesciences.org/service-category/cro/) ## Event Categories - [Industry Events](https://www.califesciences.org/events-calendar/category/industry-events/) - [Industry Supported](https://www.califesciences.org/events-calendar/category/industry-supported/) - [Industry Collaboration \& Networking](https://www.califesciences.org/events-calendar/category/industry-collaboration-networking/) - [Professional Development](https://www.califesciences.org/events-calendar/category/professional-development/) - [California Life Sciences](https://www.califesciences.org/events-calendar/category/california-life-sciences/) ## Optional - [Sitemap index](https://www.califesciences.org/sitemap_index.xml)